Akademik Veri Yönetim Sistemi
Tezin Türü: Doktora
Tezin Yürütüldüğü Kurum: Orta Doğu Teknik Üniversitesi, Türkiye
Tezin Onay Tarihi: 2015
Tezin Dili: İngilizce
Öğrenci: Berna Kankılıç
Eş Danışman: FEZA KORKUSUZ, ERDAL BAYRAMLI
Özet:Osteomyelitis is a difficult to treat bone infection. In clinic, osteomyelitis is treated with surgical debridement followed by the antibiotic therapy. But, due to the low blood circulation in the infection area and the production of an exopolysaccharide, biofilm, by the pathogen violence the treatment. Therefore local drug delivery systems are generated. These systems transmit the effective dose to the infection area without any toxic effects. In this study, vancomycin containing PDLLA/β-TCP and PLGA/β-TCP composites were developed and characterized. Vancomycin containing PDLLA/β-TCP and vancomycin containing PLGA/β-TCP composites released 3.1 ± 0.2 mg and 3.4 ±0.4 mg vancomycin for six weeks, respectively and the released vancomycin was sufficient for MRSA susceptibility. Also, the released vancomycin inhibited the biofilm formation of Methicillin Resistant S. aureus. Vancomycin containing PDLLA/β-TCP and vancomycin containing PLGA/β-TCP composites were biocompatible with Mesenchymal Stem Cells and SaOS-2 osteosarcoma cells. The composites showed alkaline phosphatase activity at day 21. But for the RT-PCR studies conducted with the extraction medium of the composites, the vancomycin containing PDLLA/β-TCP and vancomycin containing PLGA/β-TCP composites were not induced the differentiation of mesenchymal stem cells by not expressing some of the osteogenesis related signalling molecules.